AroCell
AroCell: Changes to the Case (Redeye)
2020-06-30 07:20
Redeye significantly raises its Base Case for AroCell, given fundamental changes to the case following recent FDA filing in combination with close discussions with management. The company is transitioning to a more commercially oriented business with anticipated key activities in the coming 6-9 months. At a current market capitalization of roughly SEK 130m, we see great upside in the stock on all horizons.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se